Mechanistically, AS-IV promotes M1 macrophage polarization, suppresses PD-L1 expression, and modulates cancer-associated fibroblast function, whereas APS enhances CD8+ T cell activation and reverses immunosuppression. Here, CD8A is linked to cancer.